Imperial College London

DrTriciaTan

Faculty of MedicineDepartment of Metabolism, Digestion and Reproduction

Professor of Practice (Metabolic Medicine & Endocrinology)
 
 
 
//

Contact

 

+44 (0)20 3313 8038t.tan

 
 
//

Location

 

6N6ECommonwealth BuildingHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Behary:2019:10.2337/dc19-0449,
author = {Behary, P and Tharakan, G and Alexiadou, K and Johnson, N and Wewer, Albrechtsen NJ and Kenkre, J and Cuenco, J and Hope, D and Anyiam, O and Choudhury, S and Alessimii, H and Poddar, A and Minnion, J and Doyle, C and Frost, G and Le, Roux C and Purkayastha, S and Moorthy, K and Dhillo, W and Holst, JJ and Ahmed, AR and Prevost, AT and Bloom, SR and Tan, TM},
doi = {10.2337/dc19-0449},
journal = {Diabetes Care},
pages = {1446--1453},
title = {Combined GLP-1, oxyntomodulin, and peptide YY improves body weight and glycemia in obesity and prediabetes/type 2 diabetes: a randomized single-blinded placebo controlled study},
url = {http://dx.doi.org/10.2337/dc19-0449},
volume = {42},
year = {2019}
}

RIS format (EndNote, RefMan)

TY  - JOUR
AB - OBJECTIVE: Roux-en-Y gastric bypass (RYGB) augments postprandial secretion of glucagon-like peptide 1 (GLP-1), oxyntomodulin (OXM), and peptide YY (PYY). Subcutaneous infusion of these hormones ("GOP"), mimicking postprandial levels, reduces energy intake. Our objective was to study the effects of GOP on glycemia and body weight when given for 4 weeks to patients with diabetes and obesity. RESEARCH DESIGN AND METHODS: In this single-blinded mechanistic study, obese patients with prediabetes/diabetes were randomized to GOP (n = 15) or saline (n = 11) infusion for 4 weeks. We also studied 21 patients who had undergone RYGB and 22 patients who followed a very low-calorie diet (VLCD) as unblinded comparators. Outcomes measured were 1) body weight, 2) fructosamine levels, 3) glucose and insulin during a mixed meal test (MMT), 4) energy expenditure (EE), 5) energy intake (EI), and 6) mean glucose and measures of glucose variability during continuous glucose monitoring. RESULTS: GOP infusion was well tolerated over the 4-week period. There was a greater weight loss (P = 0.025) with GOP (mean change -4.4 [95% CI -5.3, -3.5] kg) versus saline (-2.5 [-4.1, -0.9] kg). GOP led to a greater improvement (P = 0.0026) in fructosamine (-44.1 [-62.7, -25.5] µmol/L) versus saline (-11.7 [-18.9, -4.5] µmol/L). Despite a smaller weight loss compared with RYGB and VLCD, GOP led to superior glucose tolerance after a mixed-meal stimulus and reduced glycemic variability compared with RYGB and VLCD. CONCLUSIONS: GOP infusion improves glycemia and reduces body weight. It achieves superior glucose tolerance and reduced glucose variability compared with RYGB and VLCD. GOP is a viable alternative for the treatment of diabetes with favorable effects on body weight.
AU - Behary,P
AU - Tharakan,G
AU - Alexiadou,K
AU - Johnson,N
AU - Wewer,Albrechtsen NJ
AU - Kenkre,J
AU - Cuenco,J
AU - Hope,D
AU - Anyiam,O
AU - Choudhury,S
AU - Alessimii,H
AU - Poddar,A
AU - Minnion,J
AU - Doyle,C
AU - Frost,G
AU - Le,Roux C
AU - Purkayastha,S
AU - Moorthy,K
AU - Dhillo,W
AU - Holst,JJ
AU - Ahmed,AR
AU - Prevost,AT
AU - Bloom,SR
AU - Tan,TM
DO - 10.2337/dc19-0449
EP - 1453
PY - 2019///
SN - 0149-5992
SP - 1446
TI - Combined GLP-1, oxyntomodulin, and peptide YY improves body weight and glycemia in obesity and prediabetes/type 2 diabetes: a randomized single-blinded placebo controlled study
T2 - Diabetes Care
UR - http://dx.doi.org/10.2337/dc19-0449
UR - https://www.ncbi.nlm.nih.gov/pubmed/31177183
UR - https://care.diabetesjournals.org/content/42/8/1446
UR - http://hdl.handle.net/10044/1/71396
VL - 42
ER -